VolitionRx Limited (NYSE AMERICAN: VNRX) announced that a Mayo Clinic study found elevated levels of nucleosomes in trauma patients, with higher concentrations in those who developed complications.

The peer-reviewed clinical study, published in Shock Journal, analyzed 674 trauma patients and measured nucleosome levels using Volition's Nu.Q H3.1 and Nu.Q H3R8 Citrulline biomarkers. The research found that nucleosome concentrations were elevated early after traumatic injury, particularly in patients who developed Venous Thromboembolism (VTE).

Myung S. Park, Professor of Surgery at Mayo Clinic Rochester and the study's principal investigator, stated that "levels of the H3.1 and H3R8 Citrulline nucleosomes are elevated early after traumatic injury, especially in those who developed Venous Thromboembolism." Park noted that these biomarkers could aid in early risk identification and inform targeted preventive strategies in trauma care.

The study represents a collaboration between Mayo Clinic's trauma research team and VolitionRx, a multi-national epigenetics company based in Henderson, Nevada. Dr. Andrew Retter, Medical Consultant at Volition, described the peer-reviewed publication as supporting the company's efforts to commercialize its Nu.Q NETs product.

VolitionRx develops blood tests for disease detection and monitoring, including tests for some cancers and diseases associated with NETosis such as sepsis. The company operates research facilities in Belgium, the United States, and London.

The research findings are based on information provided in a company press release. Park indicated that the Mayo Clinic team plans to continue working with Volition and expects to publish additional findings.